Assessment of the Safety and Effectiveness of a Micro-RF Skin Treatment Device (nebulyft） (ASEMRSTD)
Assessment of the Safety and Effectiveness of a Micro Radiofrequency Skin Treatment Device (nebulyft)
Study Overview
Detailed Description
This is a single-arm prospective study aimed at evaluating the safety and efficacy of nebulyft device treatment of facial areas. Nebulyft device is a low-power, radio frequency device designed to reduce facial wrinkles. 42 subjects will be enrolled in a single clinical site.
The included subjects will use the device at specified areas, including the cheek (for nasolabial fold lines), and outer eye corners (for crow's feet lines). Each side of the nasolabial fold receives 4 minutes of treatment, and each outer eye corner receives 4 minutes of treatment too. The total time for each treatment is 16 minutes. The study consists of at least five wrinkle reduction treatments a week at home for four consecutive weeks. The first treatment session will be conducted under the supervision of the principal investigator (PI), and the remaining sessions will be conducted at home, with remote assistance from the PI when necessary.
A Self-selection and Labeling Comprehension study will be conducted that includes three main questions regarding the intended use of the device, treatment areas, and the possibility of using the device according to the contraindications.
A usability study will be conducted as part of the clinical study. The study was divided into several steps. The PI must observe the test subject to ensure compliance with all the procedures.
In the first visit, the independent treatment for wrinkle reduction was performed under the investigator's observation. Patients were asked to rate the pain level and note any problems/difficulties during the treatments.
The subjects perform treatment at home for 4 continuous weeks and return for photography at the end of the treatment. They will be asked to rate the pain level of the treatment during the visit.
The subjects take final photographs 4 weeks after finishing the treatment and rate the overall satisfaction of the treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Gabriel, California, United States, 91776
- DSC Laser Skin Care Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All subjects received oral and electronic consent in accordance with local laws and regulations. Informed consent explains the nature and purpose of the study and the potential risks involved in the study, and emphasizes the voluntary nature of the test, and the subjects can exit the study at any time for any reason. All subjects can ask questions about the research and give sufficient time before signing. All informed consent must be signed before the start of the study.
- Adult subjects aged 25-65.
- The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects, and sign the Informed Consent Form, including the permission to use photography.
- The subjects should be willing to comply with the study procedure and schedule, including the follow-up visits, and will refrain from using any other or similar treatment technologies (i.e., Laser, RF, IR) for the facial condition.
- The subjects will carry on with their usual diet and exercise and will not have a significant weight change during the study.
- The subjects are able to read the User Manual in English.
- The subjects should have II-IV Fitzpatrick wrinkle skin type.
- The subjects should have visible facial wrinkles.
Exclusion Criteria:
- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
- Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance.
- Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles per investigator's discretion.
- Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases per investigator's discretion.
- Pregnancy or nursing, as well as 3-6 months post-childbirth.
- History of bleeding coagulopathies, or prolonged use of anticoagulants (daily aspirin dosing of 81 mg is acceptable).
- Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medication per investigator's discretion.
- Subjects with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regime.
- Poorly controlled endocrine disorders, such as diabetes or thyroid abnormality per investigator's discretion.
- Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash per investigator's discretion.
- History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin per investigator's discretion.
- Any surgery in treatment area within 3 months prior to treatment or before complete healing.
- Injected fillers in the treatment area in the last 6 months and Botox in the treatment area in the last 3 month.
- Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
- As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: treatment
receive treatment
|
Micro Radiofrequency Skin Treatment Device(nebulyft)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
wrinkle improvement at least one score point of Fitzpatrick wrinkle scale
Time Frame: From enrollment to the end of treatment at 8 weeks
|
Three independent board-certified dermatologists assess patient photographs taken at baseline (before treatment initiation) and compare them to those captured one month after completing the home-based treatment using the Fitzpatrick wrinkle scale, which ranges from 1 (least wrinkles) to 9 (most wrinkles).
A treatment is considered successful if at least two of the three evaluators observe reduction of at least one score-point in any of the treated areas; otherwise, it is deemed a failure.
|
From enrollment to the end of treatment at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
subjective wrinkle improvement in wrinkle appearance as measured by satisfactory questionnaires
Time Frame: From enrollment to the end of treatment at 8 weeks
|
Subjective wrinkle improvement is assessed based on participants responses to satisfaction questionnaires.
There are four questions in total, each rated on a scale of 1 to 4, where 1 indicates very dissatisfied; and 4 indicates very satisfied.
The scores from all four questions are summed up, and the total score is used to determine the participants' overall satisfaction with the treatment results.
|
From enrollment to the end of treatment at 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tony Shum, MD, DSC Laser & Skin Care Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RBTBAP202404 V1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.